Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | KIF11 | P52732 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 3/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.49 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.48 |
| ▸ | FEN1 | P39748 | 2/20 | 0.48 |
| ▸ | FABP4 | P15090 | 2/20 | 0.46 |
| ▸ | GPR3 | P46089 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16429040 | 0.86 | BACE1 (0.56) | ALOX5KIF11BACE1ALDH1A1PTGDR2 | |
| SCHEMBL21944868 | 0.85 | GSTP1 (0.49) | KIF11BACE1PTGDR2ALOX5APFEN1 | |
| SCHEMBL27781322 | 0.83 | KIF11 (0.58) | KIF11BACE1ALDH1A1PTGDR2HPGD | |
| SCHEMBL30023096 | 0.83 | KIF11 (0.58) | KIF11BACE1ALDH1A1PTGDR2HPGD | |
| SCHEMBL21944790 | 0.82 | ALOX5AP (0.49) | KIF11ALDH1A1HSD17B10CNR2CNR1 | |
| SCHEMBL21945443 | 0.81 | PTGDR2 (0.51) | ALOX5KIF11PTGDR2CNR2CNR1 | |
| SCHEMBL14832292 | 0.80 | CNR1 (0.56) | KIF11CNR2CNR1ALOX5APFEN1 | |
| SCHEMBL30545136 | 0.80 | CNR1 (0.56) | KIF11CNR2CNR1ALOX5APFEN1 | |
| SCHEMBL13454410 | 0.80 | ALDH1A1 (0.57) | ALOX5BACE1ALDH1A1HPGDBCL2L1 | |
| SCHEMBL5121382 | 0.80 | APP (0.57) | KIF11BACE1ALDH1A1PTGDR2ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109503686-B | Novel nucleoside phosphoramidate compounds and uses thereof | 南京圣和药业股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-108546277-B | Novel nucleoside phosphoramidate compounds and uses thereof | 南京圣和药业股份有限公司 | 2021-05-07 | — | — | CN | disclosed |
| CN-108314697-B | Novel nucleoside phosphoramidate compounds and uses thereof | 南京圣和药业股份有限公司 | 2021-05-07 | — | — | CN | disclosed |
| US-10799510-B2 | Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists | GENFIT (FR) | 2020-10-13 | — | — | US | disclosed |
| US-20170296548-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | GENFIT (FR) | 2017-10-19 | — | — | US | disclosed |
| US-9586963-B2 | Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists | GENFIT (FR) | 2017-03-07 | — | — | US | disclosed |
| US-20150038503-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | GENFIT (FR) | 2015-02-05 | — | — | US | disclosed |
| EP-2760866-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | Genfit (FR) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013045519-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | GENFIT (FR) | 2013-04-04 | — | — | WO | disclosed |
| EP-0427829-A1 | TRIFLUOROTOLUOL COMPOUNDS AND LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GmbH (DE) | 1991-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10799510-B2 | Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists | NR1D1, NR1D2, PER2 | ALOX5 1942/4885KIF11 4382/4885BACE1 2625/4885 |
| US-20170296548-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | NR1D1, NR1D2, PER2 | ALOX5 1942/4885KIF11 4382/4885BACE1 2625/4885 |
| US-20150038503-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | NR1D1, NR1D2, PER2 | ALOX5 1942/4885KIF11 4382/4885BACE1 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.